Clover Health Investments, Corp. (CLOV) Stock Competitors & Peer Comparison
See (CLOV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CLOV | $3.83 | -4.01% | 2B | -31.92 | -$0.12 | N/A |
| UNH | $399.47 | +0.76% | 362.9B | 30.11 | $13.27 | +2.21% |
| CVS | $95.93 | +1.17% | 122.4B | 42.07 | $2.28 | +2.79% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $415.53 | +1.49% | 90.3B | 17.63 | $23.58 | +1.65% |
| CI | $289.48 | +3.14% | 76.6B | 2.55 | $113.73 | +2.13% |
| HUM | $350.08 | +0.08% | 42.1B | 37.38 | $9.37 | +1.02% |
| CNC | $62.33 | -0.59% | 30.8B | -4.77 | -$13.05 | N/A |
| MOH | $190.86 | -1.01% | 9.9B | 51.30 | $3.72 | N/A |
| OSCR | $24.51 | +3.86% | 6.4B | -45.38 | -$0.54 | N/A |
Stock Comparison
CLOV vs UNH Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, UNH has a market cap of 362.9B. Regarding current trading prices, CLOV is priced at $3.83, while UNH trades at $399.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas UNH's P/E ratio is 30.11. In terms of profitability, CLOV's ROE is -0.17%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check UNH's competition here
CLOV vs CVS Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, CVS has a market cap of 122.4B. Regarding current trading prices, CLOV is priced at $3.83, while CVS trades at $95.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas CVS's P/E ratio is 42.07. In terms of profitability, CLOV's ROE is -0.17%, compared to CVS's ROE of +0.04%. Regarding short-term risk, CLOV is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CVS's competition here
CLOV vs ANTM Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CLOV is priced at $3.83, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CLOV's ROE is -0.17%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to ANTM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check ANTM's competition here
CLOV vs ELV Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, ELV has a market cap of 90.3B. Regarding current trading prices, CLOV is priced at $3.83, while ELV trades at $415.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas ELV's P/E ratio is 17.63. In terms of profitability, CLOV's ROE is -0.17%, compared to ELV's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check ELV's competition here
CLOV vs CI Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, CI has a market cap of 76.6B. Regarding current trading prices, CLOV is priced at $3.83, while CI trades at $289.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas CI's P/E ratio is 2.55. In terms of profitability, CLOV's ROE is -0.17%, compared to CI's ROE of +0.15%. Regarding short-term risk, CLOV is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CI's competition here
CLOV vs HUM Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, HUM has a market cap of 42.1B. Regarding current trading prices, CLOV is priced at $3.83, while HUM trades at $350.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas HUM's P/E ratio is 37.38. In terms of profitability, CLOV's ROE is -0.17%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CLOV is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check HUM's competition here
CLOV vs CNC Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, CNC has a market cap of 30.8B. Regarding current trading prices, CLOV is priced at $3.83, while CNC trades at $62.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas CNC's P/E ratio is -4.77. In terms of profitability, CLOV's ROE is -0.17%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CLOV is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CNC's competition here
CLOV vs MOH Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, MOH has a market cap of 9.9B. Regarding current trading prices, CLOV is priced at $3.83, while MOH trades at $190.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas MOH's P/E ratio is 51.30. In terms of profitability, CLOV's ROE is -0.17%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CLOV is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check MOH's competition here
CLOV vs OSCR Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, OSCR has a market cap of 6.4B. Regarding current trading prices, CLOV is priced at $3.83, while OSCR trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas OSCR's P/E ratio is -45.38. In terms of profitability, CLOV's ROE is -0.17%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CLOV is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.Check OSCR's competition here
CLOV vs ALHC Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, ALHC has a market cap of 3.2B. Regarding current trading prices, CLOV is priced at $3.83, while ALHC trades at $15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas ALHC's P/E ratio is 153.70. In terms of profitability, CLOV's ROE is -0.17%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CLOV is more volatile compared to ALHC. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check ALHC's competition here
CLOV vs BHG Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CLOV is priced at $3.83, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas BHG's P/E ratio is -0.12. In terms of profitability, CLOV's ROE is -0.17%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CLOV is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.Check BHG's competition here
CLOV vs CABR Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, CABR has a market cap of 19M. Regarding current trading prices, CLOV is priced at $3.83, while CABR trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas CABR's P/E ratio is -1.87. In terms of profitability, CLOV's ROE is -0.17%, compared to CABR's ROE of -3.00%. Regarding short-term risk, CLOV is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.Check CABR's competition here
CLOV vs BMGL Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, BMGL has a market cap of 10.2M. Regarding current trading prices, CLOV is priced at $3.83, while BMGL trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas BMGL's P/E ratio is -1.21. In terms of profitability, CLOV's ROE is -0.17%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CLOV is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.Check BMGL's competition here
CLOV vs MRAI Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, MRAI has a market cap of 9.9M. Regarding current trading prices, CLOV is priced at $3.83, while MRAI trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas MRAI's P/E ratio is -0.10. In terms of profitability, CLOV's ROE is -0.17%, compared to MRAI's ROE of +0.50%. Regarding short-term risk, CLOV is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.Check MRAI's competition here
CLOV vs UAM Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CLOV is priced at $3.83, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas UAM's P/E ratio is N/A. In terms of profitability, CLOV's ROE is -0.17%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CLOV is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check UAM's competition here
CLOV vs GTS Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CLOV is priced at $3.83, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas GTS's P/E ratio is 10.41. In terms of profitability, CLOV's ROE is -0.17%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CLOV is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check GTS's competition here
CLOV vs AET Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, AET has a market cap of 0. Regarding current trading prices, CLOV is priced at $3.83, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas AET's P/E ratio is N/A. In terms of profitability, CLOV's ROE is -0.17%, compared to AET's ROE of +0.11%. Regarding short-term risk, CLOV is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check AET's competition here
CLOV vs MGLN Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CLOV is priced at $3.83, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -31.92, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CLOV's ROE is -0.17%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CLOV is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check MGLN's competition here